NFAT1 and NFAT5 act as pro-invasive and promigratory transcription factors in breast carcinoma, contributing to the formation of metastases. We report that NFAT3 is specifically expressed in estrogen receptor a positive (ERA þ ) breast cancer cells. We show that NFAT3 inhibits by itself the invasion capacity of ERA þ breast cancer cells and needs to cooperate with ERA to inhibit their migration. Conversely, NFAT3 downregulation results in actin reorganization associated with increased migration and invasion capabilities. NFAT3 signaling reduces migration through inhibition of Lipocalin 2 (LCN2) gene expression. Collectively, our study unravels an earlier unknown NFAT3/LCN2 axis that critically controls motility in breast cancer.
Introduction
Breast cancer is a leading cause of morbidity in women worldwide. The main reason of death for these patients is not the primary tumor, but distant metastases, which are directly linked to the migratory and invasive phenotype of the cancer cells (Friedl and Wolf, 2003) . Invasion is a complex process that requires both (i) the capacity of the cells to destroy and reorganize the extracellular matrix and (ii) their capacity to migrate, the latter being necessary, but not sufficient, for invasion.
The family of NFAT transcription factors comprises five genes (NFAT1 to 5). NFAT1, NFAT2, NFAT3 and NFAT4 were first identified as T cell transcription factors and bind the human IL-2 promoter after activation (Shaw et al., 1988) , whereas NFAT5 is induced by osmotic stress (Lopez-Rodriguez et al., 1999) . It is now well documented that NFAT proteins are also present in non-immune cells (Ho et al., 1998; Molkentin et al., 1998; Ranger et al., 2000; Jauliac et al., 2002; Hill-Eubanks et al., 2003; Benedito et al., 2005) and regulate a variety of signaling pathways involved in cell growth and development (Xanthoudakis et al., 1996; Baksh et al., 2002; Chuvpilo et al., 2002) . Owing to their function in critical signaling pathways controlling cell fate, one could expect that disturbing signaling of NFAT factors may impact on carcinogenesis. Indeed, molecular pathways involving specific members of the NFAT family were recently highlighted in the migratory and invasive capacities of breast cancer cells (Jauliac et al., 2002) . Moreover, there is growing evidence for a function of the NFAT factors in carcinogenesis (Mancini and Toker, 2009) . Genomic amplification of NFAT1 has been observed in pancreatic cancer (Holzmann et al., 2004) , and ectopic activation of NFAT2 induces over-expression of c-myc (Buchholz et al., 2006) . Ectopic expression of constitutively activated NFAT2 in preadipocytes induces their transformation and tumors in nude mice (Neal and Clipstone, 2003 ). Furthermore, NFAT5 expression level is a prognostic marker in breast cancer (Ayers et al., 2004) or in non-small cell lung cancer patients (Zhong et al., 2004) .
The ability of tumor cells to form metastases is one of the critical determinants of malignancy. Lipocalin 2 (LCN2) is a secreted protein of the Lipocalin family (Flower, 1996) . LCN2 can be induced under diverse inflammatory conditions (Nielsen et al., 1996) and has a function in cell survival (Devireddy et al., 2001) . High LCN2 expression levels are associated with malignancy in different cancers including ovarian (Lim et al., 2007) , pancreatic (Furutani et al., 1998) , lung and colon cancers (Friedl et al., 1999) . Recently, LCN2 has been implicated in tumorigenesis and formation of metastases in murine breast cancer models (Shi et al., 2008; Leng et al., 2009; Yang et al., 2009) . A potential function for LCN2 in the migratory capacity of colon cells (Playford et al., 2006) and tissue invasion by leukemia cells (Leng et al., 2008) has also been documented. The LCN2 gene is specifically downregulated in estrogen receptor a positive (ERA þ ) breast cancer patients (Stoesz et al., 1998) and has been reported as a predictor of breast cancer progression (Bauer et al., 2008; Provatopoulou et al., 2009) . It has been clearly shown that expression of ERA is associated with more differentiated, less invasive tumors. Moreover, numerous clinical studies suggest that estrogens and their receptors protect the patients against the apparition of metastases (Li et al., 2001) , and breast carcinomas cell lines that express the ERA are less invasive than cells lacking its expression (Thompson et al., 1988; Platet et al., 2000) . Moreover, when ERA þ breast carcinoma cell lines are re-implanted in mice, tumors arise only in the presence of estrogen and they are poorly metastatic compared with the cells that do NFAT3/LCN2 axis inhibits breast carcinoma motility M Fougère et al not express ERA (Price et al., 1990) . Indeed, some studies have reported that NFAT3 is specifically present in breast cancer patients who express ERA (Gruvberger et al., 2001; Zhang et al., 2005) . In this report, we unravel a new regulatory circuit, wherein NFAT3 is an anti-motility factor that acts by blocking LCN2 expression in ERA þ breast cancer.
Results
NFAT genes are differentially expressed in ERA þ and ERAÀ breast cancer cells We used six distinct breast cancer cell lines to evaluate the distribution of NFAT genes relative to ERA expression (ERA þ : MCF-7, T-47D, ZR-75-1, BT-474; ERAÀ: MDA-MB-231, MDA-MB-453) and a melanoma cell line MDA-MB-435 described earlier as a breast cancer cell line (Ellison et al., 2002) . Using primers that specifically amplified the different NFAT splice isoforms, we found that RNA of every gene-but NFAT3-was similarly detected independently of the cells' ERA status ( Figure 1A , left panel). Remarkably, NFAT3 expression at the RNA as well as at the protein level was restricted to ERA þ cells ( Figure 1A , right panel), whereas neither NFAT1 nor NFAT2 proteins were detected in ERA þ cells (Supplementary Figures S1 and S2) ; NFAT1 protein was present only in ERAÀ cells, NFAT2 protein was not detected in the ERAÀ and ERA þ cells, and NFAT5 and NFAT4 proteins were found in both types of cells (Supplementary Figure S1 ).
NFAT3 regulates actin organization and inhibits invasion and migration
To evaluate whether NFAT3 protein had an impact on cell morphology, ERA þ cancer cells were treated with two different siRNA, which reduced NFAT3 expression by 90% without affecting that of NFAT5 or of NFAT4 ( Figure 1B , upper left panel) or of NFAT1 and NFAT2 (Supplementary Figure S2) . Such treatment did not lead to cell apoptosis, as assayed by annexin V labeling (unpublished data). The absence of NFAT3 resulted in dramatic actin redistribution and condensation at the cell periphery, with formation of membrane ruffles and lamella structures ( Figure 1B , lower panels b and c) typical of migrating cells. Indeed, both the invasive and migratory capacities of the NFAT3-depleted cells were increased relative to cells transfected with control siRNA ( Figure 1B , upper right panel). As a control, ectopic expression of the constitutive active N-terminal deletion mutant of NFAT3, DNFAT3 (Molkentin et al., 1998) , not targeted by the siRNA for NFAT3, was sufficient to prevent increased invasion elicited by depletion of endogenous NFAT3 (Supplementary Figure S3) . We, therefore, tested whether higher NFAT3 level in ERA þ cells could impact invasion and migration. Indeed, when NFAT3 and DNFAT3 were transiently transfected in ERA þ breast cancer cells, the levels of ectopic NFAT3 was clearly upregulated compared with the endogenous NFAT3 level (Supplementary Figure S4 ) and this resulted in decreased invasion and migration ( Figure 1C ).
These data indicate that, in contrast to NFAT1 and NFAT5 (Jauliac et al., 2002) , NFAT3 is an anti-invasive and anti-migratory factor for ERA þ cells.
NFAT3 cooperates with ERA to block migration
We then evaluated whether NFAT3 interacted with ERA to elicit its anti-invasive and anti-migratory effects. We first attempted to downregulate ERA expression with siRNA in ERA þ cells. Unfortunately, the cells died in the absence of ERA (data not shown). To circumvent this difficulty, we used ERAÀ cells in which ERA could be re-introduced or not. In this model, NFAT3 clearly inhibited invasion in the absence of ERA ( Figure 2a , left panel), but it had no effect on ERAÀ cells' migration ( Figure 2a , right panel). How- .4], 150 mM NaCl, 1 mM EDTA, 1% NP-40, 0.5% sodium deoxycholate, 1 mM PMSF, 1 mM NaF, 1 mM Na3VO4) supplemented with proteases inhibitors. The lysates were resolved by SDS-PAGE and immunoblotted with anti-NFAT3 and anti-actin; (*) indicates a non-specific band. (b, left panel) Western blot for NFAT3, NFAT4, NFAT5 and actin of total lysates of T-47D cells 48 h post-transfection with siRNA directed against endogenous NFAT3 (15 nM). (B, right panel) T-47D cells transiently transfected with control siRNA or siRNA directed against endogenous NFAT3 (siRNA NFAT3) with Dharmafect-1 for 48 h as indicated by the manufacturer; 48 h post-transfection, cells were tested for their ability to invade and migrate. Invasion and migration assays were performed essentially as described (Jauliac et al., 2002) using insert with 8-mm membrane chambers coated with Matrigel for invasion, but not for migration. (B, lower panel) T47-D cells were grown on coverslips in 12-well plates and fixed with 4% paraformaldehyde in phosphate-buffered saline and permeabilized with 0.1% Triton X-100 48 h post-transfection with siRNA directed against endogenous NFAT3 (siRNA1 or siRNA2). The actin cytoskeleton was stained with rhodamine phalloidin. Images were acquired by confocal microscopy on a Zeiss LSM 510 META confocal laser microscope (Zeiss) with a Plan Apochromat 63X N.A.1.4 objective using the LSM 510 software (Zeiss). Arrows point to membrane ruffles and lamella structures (B, C). Bar scale, 10 mm. (C) T-47D cells transiently transfected with NFAT3 or DNFAT3 vectors, both tagged with the T7 epitope, or a control vector (vector), were tested for the ability to invade and migrate. Immunoblotting with an anti-T7 (NFAT3 or DNFAT3) antibody is shown. In all cases, the ratio of invasion and migration is presented as fold invasion or migration relative to the empty control vector or control siRNA. All results are representative of three independent experiments (bars, s.e.; *Po0.05; **Po0.01). , required for the hormone-independent action of ERA (Dutertre and Smith, 2003; Fowler et al., 2004) , were able to cooperate with NFAT3 ( Figure 2a , right panel), suggesting that NFAT3 inhibition of migration in the presence of ERA is hormone independent and relies on active gene transcription. Indeed, when migration and invasion of ERA þ cells were assessed in the presence of estradiol (E2) (Figure 2b ) or of an anti-estrogen (ICI) (Figure 2c ) in media without red phenol toward NIH3T3 medium produced in stripped serum in media without red phenol, NFAT3 still blocked migration and invasion. All together, these results indicate that the cooperation of ERA with NFAT3 to inhibit the migration is hormone independent. These results highlight two distinct pathways to regulate breast cancer cell motility: (i) migration is regulated by NFAT3 in cooperation with ERA, but not by ERA alone and (ii) invasion is regulated by NFAT3 alone indicating that genes targeted by ERA might not be key genes to regulate invasion.
NFAT3 inhibits the expression of LCN2
We realize gene chip experiments with NFAT3 siRNA in ERA þ T47D breast cancer cells to find potential NFAT3 target genes. We found several genes that are regulated by NFAT3 downregulation by more than twofold (95% confidence level). Of these genes, LCN2, a gene associated with breast cancer metastasis, was upregulated two-to fourfold in the absence of NFAT3 (data not shown). LCN2 has been implicated in the formation of metastases in murine breast cancer models (Shi et al., 2008; Leng et al., 2009; Yang et al., 2009) and it has been identified as one of the genes downregulated in ERA þ breast cancers (Stoesz et al., 1998) . To validate the results from our gene chip analysis, we performed quantitative real-time PCR (Q-PCR) on total RNA from the ERA þ T-47D breast cancer cells. As shown in Figure 3a , left panel, in the absence of NFAT3 (siRNA NFAT3), cells display a threefold increased expression of LCN2 mRNA compared with control cells (control siRNA). These results suggest that NFAT3 might regulate LCN2 mRNA transcription. When we look at the cellular distribution of endogenous NFAT3, we found that it localized both in the cytosol and nucleus, as for ectopic NFAT3 and DNFAT3 (Supplementary Figure S5 ), and treatment of the cells with siRNA-targeted NFAT3 completely blocked endogenous NFAT3 expression in both compartments (Figure 3a , middle panel). To confirm this transcriptional link, we repeated the same experiment as in Figure 3a , left panel, in the presence of a transcriptional inhibitor (actinomycin D), and now increase of LCN2 mRNA by NFAT3 depletion was completely abolished (Figure 3a, right panel) . As we found a transcriptional link between LCN2 mRNA expression and NFAT3, we look at the LCN2 promoter and identify six potential NFAT-binding sites (Supplementary Figure S6) . We realized ChIP experiments to evaluate whether NFAT3 could interact directly with the LCN2 promoter and did not find any direct binding on the LCN2 promoter, suggesting that these NFAT-binding sites are not NFAT3-binding sites in vivo (data not shown). We, therefore, made the hypothesis that NFAT3 might regulate indirectly, by an unknown factor, the expression of the LCN2 mRNA. We cloned the LCN2 gene promoter and fused it to the Luciferase gene. We found that NFAT3 downregulation increased LCN2 promoter activity by threefold relative to cells transfected by control siRNA (Figure 3b, left panel) . Conversely, expression of DNFAT3 in ERA þ and ERAÀ cells (Figure 3b , middle and right panel) was sufficient to repress LCN2 promoter activity independently of ERA expression (Figure 3b, right panel) . One other possibility for ERA to cooperate with NFAT3 would be that NFAT3 regulates ERA transcriptional activity and, therefore, participates in the regulation of some ERA's target genes to modulate LCN2 protein stability. We excluded this hypothesis, as NFAT3 was not able to modulate ERA activity measured on an ERE element fused to the Luciferase gene in our model (Supplementary Figure S7 ). Therefore, we favor the hypothesis that ERA targets independently of NFAT3-specific ERA's target genes, yet to be identified, to cooperate with the downregulation of LCN2 expression to inhibit migration. To confirm the expression of LCN2 at the protein level, we performed immunoblotting analysis on cell lysates of ERA þ and ERAÀ cells. Western blotting confirmed that LCN2 protein was expressed at higher levels in ERAÀ breast cancer cells and was below the antibody sensitivity in ERA þ (Figure 3c, left panel) . To further characterize the LCN2 protein expression in breast cancer cells, we performed, on the conditioned mediums of ERA þ and ERAÀ cells, an LCN2 ELISA assay more sensitive than the western blot. Indeed, the results indicate that ERAÀ breast cancer cells express fourfold more of the level of LCN2 protein found in Figure 2 NFAT3 alone inhibits invasion and cooperates with ERA to block migration. (a) MDA-MB-231 cells were transiently transfected with NFAT3, DNFAT3, ERA (67kD), ERA-DA/B (46kD), ERA-DBD*(67kD) or control (vector) vectors alone or in combination; 24 h after transfection, cells were harvested, resuspended in serum-free media containing 0.1% BSA, added in triplicates to the inserts and allowed to invade or migrate toward NIH3T3-conditioned media. Immunoblottings with anti-T7 (NFAT3 or DNFAT3) and anti-ERA antibodies are shown. (b, c) T-47D cells were transiently transfected with NFAT3, DNFAT3 or control vectors (vector) and cultured with stripped serum in media without red phenol for 24 h; 24 h later, cells were harvested, resuspended in serum-free media without red phenol containing 0.1% BSA with E2 at 10 nM or ICI at 100 nM or respective vehicule (Ethanol, DMSO), added in triplicates to the inserts, and allowed to invade or migrate toward NIH3T3-conditionned media produced in media without red phenol. Immunoblottings with the anti-T7 (NFAT3 or DNFAT3) antibody are shown. All results are representative of three independent experiments (bars, s.e.; *Po0.05; **Po0.01). NFAT3/LCN2 axis inhibits breast carcinoma motility M Fougère et al LCN2 mRNA, NFAT3 downregulation by siRNA was sufficient to increase LCN2 protein level in ERA þ cells (Figure 3c, right panel) .
We next examined a panel of patients' gene expression data that compared ERA þ and ERAÀ breast cancers (Bertheau et al., 2007) and confirmed that NFAT3 was mainly highly expressed among ERA þ patients, whereas LCN2 was rather upregulated in ERAÀ patients and downregulated in ERA þ patients (Figure 4a ).
All together, these results show that the LCN2 gene is indirectly repressed by NFAT3 in ERA þ breast cancer cells and is more expressed both in breast cancer cell lines and breast cancer patients lacking NFAT3 and ERA.
LCN2/NFAT3 axis regulates migration and invasion As LCN2 expression can be inhibited by NFAT3, we then examined whether LCN2 contributed to NFAT3-dependent regulation of the invasive and migratory capacities of breast cancer cells. Reducing endogenous LCN2 was sufficient to decrease invasion in both ERA þ and ERAÀ cells (Figure 4b , ERA þ and ERAÀ) without any effect on apoptosis (Supplementary Figure S8) . A recent study indicates that reducing endogenous LCN2 by siRNA induces an increase of ERA expression (Yang et al., 2009 ); we did not see such effects on ERA expression in ERA þ T-47D cells treated with the siRNA of LCN2 (Supplementary Figure S8) . In contrast to invasion, lack of endogenous LCN2 was not sufficient to reduce the migratory capacity of ERAÀ cells (Figure 4b , ERAÀ, right panel), although it was sufficient in this respect as regards ERA þ cells (Figure 4b, ERA þ , left panel) . Thus, decreasing endogenous LCN2 expression parallels, in both ERA þ and ERAÀ cells, the effect of NFAT3 on migration and invasion.
To assess whether LCN2 downregulation was required for NFAT3 to reduce the migration and invasion capacities of breast cancer cells, we examined whether adding recombinant human LCN2 to the medium would be sufficient to reverse such NFAT3 effects. We verify that effectively LCN2 entered the cells and was active by testing known targets of LCN2 (Zhang et al., 2008) (Supplementary Figure S9) . Indeed, in the presence of LCN2, NFAT3 was still able to inhibit invasion for ERA þ and ERAÀ cells (Figures 4c and d , left panels), but its effect on migration was then completely reversed for both cell types (Figures 4c and  d, right panels) . LCN2 did not reverse the inhibition of migration elicited by a dominant negative form of Rac1 (Supplementary Figure S10) , suggesting that downregulation of LCN2 is specifically required for NFAT3 to block migration.
Altogether, these results show that LCN2 downregulation occurs downstream of NFAT3 to achieve the inhibition of migration.
Discussion
Metastasis formation is a complex process that requires cancer cell migration and invasion, the former being a later event necessary, but not sufficient, for invasion to occur. Here, we show that NFAT3 is specifically expressed in ERA þ cells and inhibits both these cells' migration and invasion capacities. Downstream NFAT3, we further identify a key target gene, LCN2, transcriptionaly repressed by NFAT3. Recently, LCN2 has been implicated in the pro-invasive and promigratory capacities of breast carcinoma (Shi et al., 2008; Yang et al., 2009) . In our hands, blocking LCN2 expression was indeed sufficient to recapitulate the effects of NFAT3 on both these capacities. Conversely, recombinant LCN2 was sufficient to rescue the inhibition of migration elicited by NFAT3. These data unravel that the migratory capacity of ERA þ cells is mediated by a critical NFAT3/LCN2 axis. Adding back recombinant LCN2 on ERA þ cells was not able to recapitulate the effect of downregulation of NFAT3 on actin reorganization (data not shown), suggesting that LCN2 might target other migration-regulating mechanisms. Indeed, one study has shown that LCN2 is able to activate the ERK pathway (Gwira et al., 2005) and ERK seems to be an important actor of breast cancer cell migration (Krueger et al., 2001; Irie et al., 2005) . However, further studies will be required to investigate the potential function of the ERK pathway downstream LCN2 to regulate migration in breast cancer cells.
Mechanistically, we show that NFAT3 has a specific anti-invasive capacity in breast cancer cells and needs to cooperate with ERA to achieve inhibition of migration. Figure 4 LCN2 gene expression is associated with an ERAÀ and NFAT3-negative status in breast cancer patients and downregulation of LCN2 gene expression by NFAT3 is a required limiting effect to inhibit migration and is dispensable to blunt invasion. (a) Hierarchical clustering based on LCN2 and NFAT3 genes in 37 tumors analyzed with Affymetrix-grade RNA. Annotations: ERA (immunohistochemistry); p, positive; n, negative; 2-25 refers to the earlier reported patients' references (Bertheau et al., 2007) . NFAT3/LCN2 axis inhibits breast carcinoma motility M Fougère et al However, we could not confirm (data not shown) the reports indicating that NFAT3 can associate with ERA and did not see any effects of NFAT3 on ERA transcriptional activity (Zhang et al., 2005; Qin et al., 2008) . Interestingly, although both ERA þ cell migration and invasion were inhibited by LCN2 downregulation, the later was not enough to inhibit migration in ERAÀ cells, suggesting that cooperation of other critical genes was then required. The data from our study suggest that these genes that cooperate with the downregulation of LCN2 by NFAT3 are certainly genes targeted by ERA. In contrast, for invasion, rescue by recombinant LCN2 was not able to prevent inhibition of invasion elicited by NFAT3, suggesting that NFAT3 might target other key genes in addition to LCN2 to modulate the invasion. We could make the hypothesis that these LCN2-independent mechanisms mediated by NFAT3 to inhibit the invasion relay on the regulation of specific invasive genes similar to the matrix remodeling proteases (Supplementary Figure S11) . Our findings further highlight the versatility of the NFAT transcription factors family in modulating the behavior of cancer cells and imply that perturbing this novel ERA/NFAT3/LCN2 axis could be a strategy to limit the aggressiveness of ERA þ breast cancer cells.
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